

References: Clinical Considerations

1. Health Canada Drug Product Database [Jardiance](#)
2. Health Canada Drug Product Database [Invokana](#)
3. Health Canada Drug Product Database [Forxiga](#)
4. US Food and Drug Administration [Jardiance](#)
5. US Food and Drug Administration [Invokana](#)
6. US Food and Drug Administration [Farxiga](#)
7. McGuire D et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis JAMA Cardiol 2021;6: 148-158 [PMID 33031522](#)
8. Zannad F et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials Lancet 2020; 396:819-829 [PMID 32877652](#)
9. Oshima M et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International 2021;99: 999-1009. [PMID 33316282](#)
10. Iskander C et al. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. CMAJ 2020; 192:E351-60. [PMID 32392523](#)
11. Douros A et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Int Med 2020; 173:417-425. [PMID 32716707](#)
12. [US Food and Drug Administration 2015 SGLT2 inhibitors and diabetic ketoacidosis](#)
13. [Health Canada 2016 SGLT2 inhibitors and diabetic ketoacidosis](#)
14. [European Medicines Agency 2016 SGLT2 inhibitors and diabetic ketoacidosis](#)
15. Handelsman Y et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT2 inhibitors and diabetic ketoacidosis. Endocr Pract 2016; 22: 753-62. [PMID 27082665](#)
16. Diabetes Canada position statement on low-carbohydrate diets for adults with diabetes: a rapid review. Can J Diabetes 2020; 44: 295-299. [PMID 32475469](#)
17. Mistry S, Eschler D. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clin Case Rep 2020; 7: 17-19. [PMID 33851013](#)
18. Gomez-Peralta F et al. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes. Diabetes Ther 2017; 8: 953-962. [PMID 28721687](#)
19. Woo V et al. Considerations for initiating a sodium glucose cotransporter 2 inhibitor in adults with type 2 diabetes using insulin. Can J Diabetes 2018; 42: 88-93 [PMID 28579198](#)
20. Lam D, Shaikh A. Real-life prescribing of SGLT2 inhibitors: how to handle the other medications, including glucose-lowering drugs and diuretics. Kidney360 2021; 2: 742-746. [Kidney360](#)
21. Canadian Heart Failure Society. 2020. Practical approach to SGLT2 inhibitors for treatment of cardiovascular disease. [CHFS](#)
22. Lega I et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab 2019; 21: 2394-2404. [PMID 31264755](#)
23. [US Food and Drug Administration 2018 SGLT2 inhibitors rare serious genital infections](#)
24. Perkovic V et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-2306. [PMID 30990260](#)
25. Yu O et al. Sodium glucose cotransporter 2 inhibitors and risk of below knee amputation: a multicenter observational study. Diabetes Care 2020; 43: 2444-2452. [PMID 32759360](#)
26. Fisher A et al. Sodium glucose cotransporter 2 inhibitors and the risk of urosepsis: a multi-site, prevalent, new-user cohort study. Diabetes Obes Metab 2020; 22: 1648-1658. [PMID 32383792](#)
27. Health Canada Drug Product Database [Ozempic](#)
28. Health Canada Drug Product Database [Victoza](#)

29. Health Canada Drug Product Database [Trulicity](#)
30. Health Canada Drug Product Database [Rybelsus](#)
31. US Food and Drug Administration [Ozempic](#)
32. US Food and Drug Administration [Victoza](#)
33. US Food and Drug Administration [Trulicity](#)
34. US Food and Drug Administration [Rybelsus](#)
35. Honigberg M et al. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease. A review. JAMA Cardiol 2020;5:1182-1190. [PMID 32584928](#)
36. Government of the United Kingdom. 2019. [GLP1-receptor agonists diabetic ketoacidosis insulin discontinuation](#)
37. Azoulay L et al. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Int Med 2016;176:1464-1473. [PMID 27479930](#)
38. US Food and Drug Administration [Wegovy](#)
39. Kristensen S et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-85. [PMID 31422062](#)